Navigation Links
Transcept Pharmaceuticals to Present at Two Upcoming Conferences
Date:3/2/2009

--BIO-Europe Spring(R) 2009 in Milan, Italy--

--Cowen and Company 29th Annual Health Care Conference in Boston, MA--

PT. RICHMOND, Calif., March 2 /PRNewswire-FirstCall/ -- Transcept Pharmaceuticals, Inc. (Nasdaq: TSPT) announced today that the Company will present at two upcoming conferences:

  • Glenn A. Oclassen, President and Chief Executive Officer, will present at Bio-Europe Spring(R) 2009, to be held at the Milano Convention Centre (MIC) in Milan on Tuesday, March 17, 2009, at 4:30 p.m. CET (10:30 a.m. ET).
  • Thomas P. Soloway, Senior Vice President and Chief Financial Officer, will present at the Cowen and Company 29th Annual Health Care Conference, to be held at the Boston Marriott Copley Place in Boston, MA, on Tuesday, March 17, 2009, at 9:30 a.m. ET.

An audio webcast of Mr. Soloway's presentation will be available live and archived for 30 days at http://www.transcept.com/.

About Transcept Pharmaceuticals

Transcept Pharmaceuticals is a specialty pharmaceutical company focused on the development and commercialization of proprietary products that address important therapeutic needs in the field of neuroscience. On January 30, 2009, Transcept completed a merger with Novacea, Inc. As part of the transaction, Novacea changed its name to "Transcept Pharmaceuticals, Inc." and its NASDAQ ticker symbol to "TSPT." The combined company resources resulting from the merger are expected to enable Transcept to successfully commercialize its lead product candidate, Intermezzo(R). If approved, Intermezzo(R) is positioned to be the first commercially available sleep aid specifically for use in the middle of the night when patients awaken and have difficulty returning to sleep. Intermezzo(R) Phase 3 clinical trials have been completed and, on September 30, 2008, Transcept submitted a New Drug Application (NDA) for Intermezzo(R) to the U.S. Food and Drug Administration (FDA) which was accepted for filing on December 15, 2008. The FDA has assigned a PDUFA date of July 30, 2009, to the Intermezzo(R) NDA.

For further information, please visit the company's website at: www.transcept.com.

Safe Harbor

This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). Transcept disclaims any intent or obligation to update these forward-looking statements, and claims the protection of the Safe Harbor for forward-looking statements contained in the Act. Examples of such statements include, but are not limited to, statements relating to Intermezzo(R) being the first commercially available sleep aid in its target indication. Such statements are based on management's current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to: positive results in clinical trials may not be sufficient to obtain FDA approval; physician or patient reluctance to use Intermezzo(R), if approved; potential alternative therapies; maintaining adequate patent or trade secret protection without violating the intellectual property rights of others; and other difficulties or delays in, or unexpected expenses incurred in connection with, obtaining regulatory approval, market acceptance and commercialization of Intermezzo(R).

    Contacts:

    Transcept Pharmaceuticals, Inc.
    Michael Gill
    Director of Communications
    (510) 215-3575
    mgill@transcept.com

    The Ruth Group
    Investors / Media
    Stephanie Carrington / Jason Rando
    (646) 536-7017 / 7025
    scarrington@theruthgroup.com
    jrando@theruthgroup.com


'/>"/>
SOURCE Transcept Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
2. Transcept Pharmaceuticals, Inc. to Present at 2007 BIO Investor Forum
3. Transcept Pharmaceuticals to Present at 19th Annual Piper Jaffray Health Care Conference
4. Transcept Pharmaceuticals to Present at RBC Capital Markets 2007 Healthcare Conference
5. Transcept Pharmaceuticals to Present at the 2008 Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference
6. Transcept Pharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
7. Transcept Pharmaceuticals to Present at the Susquehanna Financial Groups SIGnificant Investment Options in Healthcare Conference
8. Transcept Pharmaceuticals to Present at Cowen and Companys 27th Annual Health Care Conference in Boston
9. Transcept Pharmaceuticals to Present at the BioCentury Future Leaders in the Biotech Industry Conference
10. Transcept Pharmaceuticals to Present at the Jefferies 2nd Annual Healthcare Conference
11. Transcept Pharmaceuticals, Inc. to Present at the 20th Annual Piper Jaffray Health Care Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... ... February 24, 2017 , ... ... education, networking and recognition opportunities as well as advocacy for the state and ... NJ on February 23. The Council's Innovation Forecast event highlights innovation throughout ...
(Date:2/24/2017)... ... 24, 2017 , ... The Smart Machine Age is here, and it’s disrupting ... percent of all jobs in the United States may be taken over by technology ... the aggressive know-it-all who steamrolls over colleagues is drawing to a close. Success will ...
(Date:2/24/2017)... McKinney, Texas (PRWEB) , ... February 24, 2017 , ... ... south to The Medical Center at Craig Ranch building at 8080 State Highway 121, ... Ranch Medical District with easy access to Highway 121. , As the practice has ...
(Date:2/24/2017)... San Diego, CA (PRWEB) , ... February 24, 2017 , ... ... announce its 2017 national conference convening academic faculty engaged in or interested in palliative ... Education and Research,” will be held in North County San Diego on Sept. ...
(Date:2/24/2017)... ... , ... Indiana Fiber Network (IFN) President and CEO Kelly C. Dyer recently ... as the Chairman of the Management Committee when IFN was originally formed in 2002 ... of investor/owners and development of the business plan. He became the first paid ...
Breaking Medicine News(10 mins):
(Date:2/24/2017)... -- Medivir AB (Nasdaq Stockholm: MVIR) today ... of Directors that will be submitted to the 2017 ... of the company,s three largest shareholders at the end ... a seat on the Nomination Committee, and the Chairman ... Committee was as follows:  ...
(Date:2/23/2017)... Visiomed, the French leader in medical ... changing the landscape of healthcare with their innovative ... custom-made solutions. Recognizing the rising demand of self-monitoring ... without walls, Visiomed has launched BewellConnect, the most ... professionals that is empowering the lives of patients. ...
(Date:2/23/2017)... -- LG Innotek hat heute die weltweit erste 70 mw ... 1,5-fache des 45-mW-Moduls der Konkurrenz. UV-C LED ... 280 nm und eignet sich damit für Sterilisationsaufgaben. Es verhindert ... Das Produkt von LG Innotek erzeugt UV-Strahlung im Bereich ... ...
Breaking Medicine Technology: